ADCT Latest Headlines

RBC Capital Sticks to Their Buy Rating for ADC Therapeutics (ADCT)

at www.tipranks.com (Thu, 22-Jan 8:58 PM)

ADCT Faces Investor Investigation Following Safety Concerns in Clinical Trial Data

Market Chameleon (Fri, 16-Jan 11:11 AM)

ADC Therapeutics Reports 89.8% Response Rate for ZYNLONTA Combo in DLBCL—Will This Change Treatment Expectations?

Market Chameleon (Thu, 4-Dec 10:08 AM)